Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)
Launched by UCONN HEALTH · Jun 27, 2012
Trial Information
Current as of July 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into a condition called Aplasia Cutis Congenita (ACC), which is a skin disorder present at birth. The main goal is to identify specific genes and other important parts of our DNA that may cause this condition. Researchers will also examine tissue samples from patients to better understand how ACC develops and affects the body.
If you or someone in your family has been diagnosed with ACC, you may be eligible to participate in this study. The trial is open to individuals with ACC, and it also welcomes unaffected family members of those with the condition. Participants can expect to contribute to important research that could help future patients by providing tissue samples and possibly answering questions about their health. This study is currently recruiting participants of all ages and genders, so if you are interested, please consider reaching out for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ACC; unaffected individuals only if part of a participating ACC family
- Exclusion Criteria:
- • No ACC unaffected individuals only as part of a participating ACC family
About Uconn Health
UConn Health, the University of Connecticut's academic medical center, is dedicated to advancing healthcare through innovative research and clinical trials. As a leading institution in medical education and patient care, UConn Health integrates cutting-edge scientific inquiry with community-focused healthcare services. With a robust portfolio of clinical trials spanning various therapeutic areas, UConn Health is committed to improving patient outcomes and enhancing the understanding of diseases through rigorous research methodologies. The center fosters collaboration among healthcare professionals, researchers, and patients to translate findings into practical applications, ultimately aiming to elevate the standard of care in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Farmington, Connecticut, United States
Patients applied
Trial Officials
Ernst J Reichenberger, PhD
Principal Investigator
UConn Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials